The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Drugmaker Eli Lilly is lowering the prices of the two lowest doses of its weight loss drug Zepbound, but they won't be ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...

(Zepbound is one of the medication's brand names.) Men, meanwhile, lost 19 percent of their body weight. This is a big move in the weight loss space. Here’s what you need to know about Zepbound.

Joshua Cohen is a Boston-based writer who covers health policy. Patients on the weight-loss drug Zepbound regained weight almost one year after stopping treatment, according to a study published ...

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...